Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. monthly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E9.53 EPS (ttm)7.69 Insider Own0.40% Shs Outstand1.34B Perf Week-3.21%
Market Cap98.07B Forward P/E11.05 EPS next Y6.63 Insider Trans-14.55% Shs Float1.30B Perf Month-3.03%
Income10.12B PEG- EPS next Q1.67 Inst Own80.90% Short Float1.41% Perf Quarter-9.90%
Sales26.11B P/S3.76 EPS this Y-22.80% Inst Trans0.06% Short Ratio2.29 Perf Half Y-8.63%
Book/sh15.64 P/B4.68 EPS next Y2.46% ROA7.30% Target Price88.95 Perf Year9.13%
Cash/sh19.05 P/C3.84 EPS next 5Y-7.24% ROE20.90% 52W Range63.76 - 89.54 Perf YTD2.25%
Dividend2.28 P/FCF11.43 EPS past 5Y36.20% ROI19.90% 52W High-18.19% Beta1.19
Dividend %3.11% Quick Ratio2.70 Sales past 5Y21.90% Gross Margin83.30% 52W Low14.89% ATR1.74
Employees10000 Current Ratio2.70 Sales Q/Q-18.70% Oper. Margin54.10% RSI (14)40.56 Volatility2.03% 2.40%
OptionableYes Debt/Eq1.64 EPS Q/Q-46.90% Profit Margin17.70% Rel Volume0.71 Prev Close72.72
ShortableYes LT Debt/Eq1.51 EarningsMay 01 AMC Payout58.70% Avg Volume7.95M Price73.25
Recom2.20 SMA20-1.62% SMA50-5.33% SMA200-5.09% Volume6,335,525 Change0.73%
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Apr-25-18 05:31PM  U.S. court upholds dismissal of $200 mln Merck verdict against Gilead Reuters
03:28PM  U.S. court upholds dismissal of $200 million Merck verdict against Gilead Reuters
Apr-24-18 04:12PM  Your Guide to Investing in Zinc-Finger (ZFN) Gene Editing Motley Fool
11:00AM  Is Bellicum Pharmaceuticals, Inc. a Buy? Motley Fool
09:31AM  This Small Biotech Is Building on a Surprising Success Motley Fool
06:31AM  3 Bargain Stocks You Can Buy Right Now Motley Fool
Apr-23-18 03:54PM  Can Gilead Sciences Incs (NASDAQ:GILD) ROE Continue To Surpass The Industry Average? Simply Wall St.
11:33AM  Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy Zacks
Apr-22-18 07:18AM  Better Buy: Gilead Sciences, Inc. (GILD) vs. Pfizer (PFE) Motley Fool
Apr-21-18 08:42AM  8%+ Dividends From My Favorite Sector Now Forbes
Apr-20-18 09:12AM  The Zacks Analyst Blog Highlights: IBM, McDonald's, Gilead, Phillips 66 and Lam Research Zacks
08:00AM  [$$] Big Buys in Alphabet, Facebook for Hot Hedge-Fund Manager Barrons.com
Apr-19-18 03:43PM  Top Research Reports for IBM, McDonald's & Gilead Zacks
02:01PM  Gilead shares drop on FDA concerns with similar Eli Lilly, Incyte drug MarketWatch
Apr-18-18 06:00PM  Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company PR Newswire
02:00PM  Why Big Biotech Stocks May Get An Earnings Boost Investopedia
12:33PM  Big Biotech ETF Can Bounce Back ETF Trends
10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks
Apr-17-18 05:00PM  Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018 Business Wire
07:30AM  New Research Coverage Highlights DexCom, Equinix, Fitbit, Gilead Sciences, Humana, and Microsoft Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-16-18 11:00AM  Gilead (GILD) Presents Encouraging Data on NASH Therapies Zacks
10:01AM  3 Growth Stocks for Successful Investors Motley Fool
Apr-13-18 06:31PM  3 Top Healthcare Stocks to Buy in April Motley Fool
10:15AM  Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress 2018 Business Wire
01:08AM  [$$] How Big Biotech Can Win Back Investors The Wall Street Journal
Apr-12-18 06:00PM  Why One Drug Flop Tanked Incyte's Stock Motley Fool
10:36AM  Silicon Valleys 10 highest-paid CEOs of 2018 may not be who you'd expect American City Business Journals
Apr-11-18 03:15PM  Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?' CNBC
11:40AM  This Little-Known Company Should Have Gilead's and Celgene's Investors Nervous Motley Fool
11:11AM  [$$] An S&P 500-Topping Advisor Dumps Its GE Stake Barrons.com
06:03AM  Is Gilead Sciences, Inc. (GILD) a Buy? Motley Fool
Apr-08-18 08:56AM  Biotech Fire Sale: 2 Top Stocks to Buy Next Week Motley Fool
07:19AM  4 Top Stocks for Investing in Pharma's Next $35 Billion Market Motley Fool
Apr-07-18 08:34AM  Is Cellectis SA Stock a Buy Now? Motley Fool
Apr-06-18 01:16PM  Biotech Investors Should Consider The Four Horsemen Forbes
08:45AM  Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again? Motley Fool
Apr-05-18 03:49PM  U.S. Medicare sets outpatient rate for Yescarta reimbursement Reuters
01:38PM  Why Doesn't Gilead Just Buy Intercept Pharmaceuticals Already? Motley Fool
06:00AM  4 Biotechs Ready for Big Rebounds Investopedia
Apr-04-18 04:21PM  Why Gilead Looks Strong In First Quarter, But These Biotechs Are Shakier Investor's Business Daily
11:08AM  Top 5 Biotech Stocks for 2018 Investopedia
06:02AM  Which Big Pharma CEOs Least Deserved Their Big Pay Increases? Motley Fool
Apr-03-18 04:09PM  Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs Investor's Business Daily
02:45PM  Is Ziopharm Oncology, Inc. a Buy? Motley Fool
08:15AM  The Zacks Analyst Blog Highlights: United Technologies, Medtronic, Gilead, Hewlett Packard and Yum! Brands Zacks
Apr-02-18 03:31PM  Top Stock Reports for United Technologies, Medtronic & Gilead Zacks
Mar-30-18 07:00AM  Better Buy: Celgene Corporation vs. Gilead Sciences Motley Fool
Mar-28-18 01:06PM  3 Big Biotech Stocks Poised for More Declines Investopedia
Mar-27-18 07:15PM  Is Gilead Sciences a Beaten-Up Biotech Stock to Buy? Motley Fool
Mar-26-18 01:39PM  Facebook stock was tanking today even before the FTC investigation news hit the wires Yahoo Finance Video
07:47AM  3 Blockbuster Drug Launches to Watch In 2018 Motley Fool
Mar-25-18 07:17AM  Better Buy: Gilead Sciences, Inc. vs. Biogen Inc. Motley Fool
Mar-24-18 11:20AM  Gilead Sciences' Investors Better Watch This Regeneron-Alnylam Deal Motley Fool
Mar-23-18 03:40PM  Will This Coming IPO Biotech Undercut Gilead, Novartis In Cancer Drugs? Investor's Business Daily
11:53AM  These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status Investor's Business Daily
Mar-21-18 03:43PM  Why It's So Dang Hard to Value Biotech Deals Motley Fool
01:06PM  NYSE trader: Facebook is too big to fail, so I'm sticking with tech stocks Yahoo Finance Video
11:19AM  GlaxoSmithKline prescribes commercial reboot for pharma division Reuters
06:08AM  Better Buy: Amgen Inc. vs. Gilead Sciences, Inc. Motley Fool
03:00AM  FOCUS-GlaxoSmithKline prescribes commercial reboot for pharma division Reuters
Mar-20-18 11:29AM  Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season Benzinga
Mar-18-18 07:19AM  Gilead Sciences' $14 Billion-Per-Year Threat Motley Fool
Mar-16-18 08:18AM  5 Must-See Quotes From AbbVie's Management Motley Fool
06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool
Mar-15-18 09:40AM  Is Gilead Sciences (GILD) a Great Stock for Value Investors? Zacks
Mar-14-18 03:30PM  Is Gilead Sciences Trying to Put Itself Out of Business? Motley Fool
01:57PM  NYSE trader: Out of control deficit spending will come to bite us someday Yahoo Finance Video
05:59AM  Grants Awarded to 13 Canadian Initiatives to Help Advance the Goal of Eliminating Chronic Hepatitis C Infection in High-Risk Populations CNW Group
Mar-13-18 02:35PM  Biogens Bargain Price May Spur a 14% Stock Gain Investopedia
08:42AM  Quebec Expands Patient Access to Chronic Hepatitis C Therapies CNW Group
Mar-12-18 12:45PM  Why Overvalued Gilead May Fall 10% Investopedia
10:33AM  Good Reasons to Stick With Biotech ETFs ETF Trends
09:20AM  The 1 Big Risk That Every Drugmaker Fears Motley Fool
09:10AM  How Pricing Can Be Vital to a Drugmaker's Profitability Motley Fool
09:05AM  How Drugmakers Approach Efficacy Is the Key to Success Motley Fool
09:00AM  Gilead Sciences Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer Business Wire
06:00AM  Why Gilead Can Beat Both the Biotechs and the S&P Investopedia
Mar-11-18 11:44AM  Here's What Lifted Sangamo Therapeutics Inc. in February Motley Fool
11:33AM  The Revolutionary New HIV Drug You've Probably Never Heard Of Motley Fool
10:14AM  Gilead Sciences Inc (NASDAQ:GILD): Ex-Dividend Is In 3 Days, Should You Buy? Simply Wall St.
Mar-10-18 03:30PM  How Biopharmas Battle for Billions Motley Fool
Mar-09-18 01:54PM  Only 5 Days Left To Cash In On Gilead Sciences Inc (NASDAQ:GILD) Dividend, Should Investors Buy? Simply Wall St.
Mar-08-18 09:30AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
Mar-06-18 01:51PM  Gilead Stock Gets Going Again Barrons.com
07:52AM  Gilead Announces Positive Data on New HIV Therapy Biktarvy Zacks
Mar-05-18 04:00PM  Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen Business Wire
12:07PM  Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine Business Wire
Mar-04-18 04:19PM  Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope Targeting Antibody in SHIV-Infected, Virally Suppressed Monkeys Business Wire
11:36AM  Here's Why Crispr Therapeutics AG Jumped Again in February Motley Fool
Mar-02-18 09:21PM  Heres Why Gilead Sciences' Jump Into Gene Editing Is Important Motley Fool
Mar-01-18 10:00PM  Gilead Sciences' History Points to Future Success Motley Fool
05:23PM  Apple's Cure for Soaring Costs? Tech-Savvy Healthcare Clinics Motley Fool
12:30PM  3 Biotech Stocks That May Be On The Verge Of Sharp Declines Investopedia
10:01AM  The Zacks Analyst Blog Highlights: Gilead, BNY Mellon, State Street, Alliant Energy and Dillard's Zacks
08:30AM  Todays Research Reports on Trending Tickers: Gilead Sciences and Amicus Therapeutics ACCESSWIRE
Feb-28-18 01:39PM  Top Analyst Reports for Gilead, BNY Mellon & State Street Zacks
01:26PM  Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo Zacks
05:59AM  Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan CNW Group
Feb-27-18 01:40PM  Gilead's Stock Rebound May Stall As Analysts Cut Forecasts Investopedia
Feb-26-18 07:00AM  Gilead Sciences: The Oncology Company? Motley Fool
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM